Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitiligo | 5 | 2025 | 126 | 3.450 |
Why?
|
| Ultraviolet Therapy | 2 | 2025 | 14 | 1.750 |
Why?
|
| Calciphylaxis | 7 | 2024 | 17 | 1.730 |
Why?
|
| Dermatology | 4 | 2023 | 74 | 1.680 |
Why?
|
| Cellulitis | 7 | 2022 | 22 | 1.120 |
Why?
|
| Kidney Failure, Chronic | 5 | 2021 | 205 | 1.010 |
Why?
|
| Vision Disorders | 1 | 2025 | 64 | 0.900 |
Why?
|
| Visual Acuity | 1 | 2025 | 126 | 0.880 |
Why?
|
| Hearing Loss | 1 | 2025 | 61 | 0.870 |
Why?
|
| Lasers, Dye | 1 | 2022 | 6 | 0.790 |
Why?
|
| Hypopigmentation | 1 | 2023 | 18 | 0.790 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2022 | 15 | 0.790 |
Why?
|
| Soft Tissue Injuries | 1 | 2022 | 21 | 0.780 |
Why?
|
| Students, Medical | 1 | 2023 | 255 | 0.700 |
Why?
|
| Child | 8 | 2025 | 4477 | 0.690 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 554 | 0.660 |
Why?
|
| Referral and Consultation | 4 | 2022 | 422 | 0.650 |
Why?
|
| Methotrexate | 2 | 2017 | 80 | 0.650 |
Why?
|
| Shigella flexneri | 2 | 2018 | 19 | 0.610 |
Why?
|
| Factor Xa Inhibitors | 1 | 2018 | 35 | 0.590 |
Why?
|
| Pyridones | 1 | 2018 | 40 | 0.590 |
Why?
|
| Child, Preschool | 4 | 2025 | 1962 | 0.580 |
Why?
|
| Pyrazoles | 1 | 2018 | 78 | 0.570 |
Why?
|
| Skin Diseases | 1 | 2019 | 83 | 0.570 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 111 | 0.570 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 114 | 0.550 |
Why?
|
| Folic Acid | 1 | 2017 | 41 | 0.540 |
Why?
|
| Host-Pathogen Interactions | 3 | 2018 | 263 | 0.510 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2016 | 8 | 0.510 |
Why?
|
| Internship and Residency | 1 | 2023 | 788 | 0.500 |
Why?
|
| Retrospective Studies | 11 | 2025 | 6545 | 0.480 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 377 | 0.470 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2015 | 20 | 0.470 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2015 | 47 | 0.460 |
Why?
|
| GTPase-Activating Proteins | 1 | 2015 | 69 | 0.450 |
Why?
|
| Virulence Factors | 1 | 2015 | 85 | 0.450 |
Why?
|
| Humans | 32 | 2025 | 62865 | 0.440 |
Why?
|
| Endocytosis | 1 | 2015 | 152 | 0.440 |
Why?
|
| Case-Control Studies | 3 | 2025 | 1115 | 0.410 |
Why?
|
| Bacterial Proteins | 2 | 2018 | 769 | 0.400 |
Why?
|
| Adolescent | 4 | 2025 | 6195 | 0.400 |
Why?
|
| Patch Tests | 2 | 2020 | 11 | 0.350 |
Why?
|
| Dermatitis, Allergic Contact | 2 | 2020 | 13 | 0.350 |
Why?
|
| Allergens | 2 | 2020 | 52 | 0.340 |
Why?
|
| Vascular Diseases | 2 | 2021 | 81 | 0.330 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 836 | 0.330 |
Why?
|
| Phototherapy | 2 | 2023 | 35 | 0.330 |
Why?
|
| Male | 12 | 2025 | 29552 | 0.330 |
Why?
|
| Home Care Services | 2 | 2020 | 98 | 0.320 |
Why?
|
| Female | 12 | 2025 | 32566 | 0.310 |
Why?
|
| Blood Culture | 2 | 2018 | 10 | 0.300 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2025 | 7 | 0.240 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2025 | 31 | 0.240 |
Why?
|
| Epigenomics | 1 | 2025 | 62 | 0.230 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2025 | 67 | 0.230 |
Why?
|
| Delayed Diagnosis | 1 | 2024 | 45 | 0.220 |
Why?
|
| Dermatologists | 1 | 2023 | 12 | 0.220 |
Why?
|
| Neoplastic Stem Cells | 1 | 2025 | 203 | 0.210 |
Why?
|
| Collagen Type VII | 1 | 2022 | 5 | 0.200 |
Why?
|
| Erythema | 1 | 2022 | 13 | 0.200 |
Why?
|
| Blister | 1 | 2022 | 17 | 0.200 |
Why?
|
| Minority Groups | 1 | 2023 | 139 | 0.190 |
Why?
|
| Recurrence | 1 | 2024 | 636 | 0.190 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 384 | 0.190 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 432 | 0.180 |
Why?
|
| Incidence | 1 | 2025 | 1373 | 0.180 |
Why?
|
| Vascular Malformations | 1 | 2021 | 22 | 0.170 |
Why?
|
| Thiosulfates | 1 | 2020 | 3 | 0.170 |
Why?
|
| Heart Murmurs | 1 | 2020 | 5 | 0.170 |
Why?
|
| Sarcoma, Myeloid | 1 | 2020 | 4 | 0.170 |
Why?
|
| Quality of Life | 2 | 2025 | 1221 | 0.170 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2020 | 16 | 0.170 |
Why?
|
| Skin Neoplasms | 1 | 2025 | 414 | 0.170 |
Why?
|
| Treatment Outcome | 2 | 2023 | 5596 | 0.160 |
Why?
|
| Heart Neoplasms | 1 | 2020 | 33 | 0.160 |
Why?
|
| Skin | 1 | 2022 | 377 | 0.160 |
Why?
|
| Middle Aged | 7 | 2024 | 17391 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 786 | 0.150 |
Why?
|
| Type III Secretion Systems | 1 | 2018 | 4 | 0.150 |
Why?
|
| Dysentery, Bacillary | 1 | 2018 | 14 | 0.150 |
Why?
|
| Skin Temperature | 1 | 2017 | 19 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 190 | 0.140 |
Why?
|
| Renal Dialysis | 1 | 2018 | 198 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2652 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2018 | 267 | 0.130 |
Why?
|
| Mutation | 1 | 2025 | 2598 | 0.130 |
Why?
|
| Retinoids | 1 | 2016 | 12 | 0.130 |
Why?
|
| Dapsone | 1 | 2016 | 10 | 0.130 |
Why?
|
| Calcineurin Inhibitors | 1 | 2016 | 23 | 0.130 |
Why?
|
| Epithelial Cells | 2 | 2018 | 390 | 0.130 |
Why?
|
| Kidney Diseases | 1 | 2018 | 174 | 0.130 |
Why?
|
| Hydroxychloroquine | 1 | 2016 | 21 | 0.130 |
Why?
|
| Thalidomide | 1 | 2016 | 34 | 0.130 |
Why?
|
| Laser Therapy | 1 | 2016 | 39 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 463 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 350 | 0.120 |
Why?
|
| Adult | 7 | 2024 | 16672 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 749 | 0.120 |
Why?
|
| Aged | 6 | 2024 | 14268 | 0.120 |
Why?
|
| Phosphatidylinositols | 1 | 2015 | 52 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 173 | 0.110 |
Why?
|
| Infant | 1 | 2019 | 1623 | 0.110 |
Why?
|
| HeLa Cells | 1 | 2015 | 533 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2018 | 706 | 0.100 |
Why?
|
| Risk Factors | 4 | 2024 | 5309 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2013 | 148 | 0.090 |
Why?
|
| Age Factors | 3 | 2020 | 1556 | 0.090 |
Why?
|
| Time Factors | 1 | 2019 | 3749 | 0.090 |
Why?
|
| Autophagy | 1 | 2013 | 225 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2016 | 551 | 0.090 |
Why?
|
| Bacteria | 1 | 2013 | 306 | 0.080 |
Why?
|
| Patient Preference | 2 | 2020 | 83 | 0.080 |
Why?
|
| Models, Biological | 1 | 2015 | 1181 | 0.080 |
Why?
|
| Young Adult | 1 | 2019 | 4655 | 0.070 |
Why?
|
| Lower Extremity | 2 | 2021 | 164 | 0.070 |
Why?
|
| Hospitals | 2 | 2020 | 393 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2013 | 794 | 0.070 |
Why?
|
| Benzamides | 1 | 2025 | 65 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2025 | 129 | 0.060 |
Why?
|
| Pyridines | 1 | 2025 | 111 | 0.060 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2025 | 144 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2025 | 255 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2025 | 251 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 521 | 0.050 |
Why?
|
| Dermatitis, Irritant | 1 | 2020 | 4 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 13 | 0.040 |
Why?
|
| Body Size | 1 | 2020 | 24 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 1455 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2020 | 78 | 0.040 |
Why?
|
| Dermatitis, Atopic | 1 | 2020 | 29 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 67 | 0.040 |
Why?
|
| Veins | 1 | 2021 | 64 | 0.040 |
Why?
|
| Chelating Agents | 1 | 2020 | 50 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 47 | 0.040 |
Why?
|
| Penis | 1 | 2020 | 30 | 0.040 |
Why?
|
| Warfarin | 1 | 2020 | 110 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1363 | 0.040 |
Why?
|
| Judgment | 1 | 2018 | 34 | 0.040 |
Why?
|
| Unnecessary Procedures | 1 | 2018 | 44 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2018 | 9 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2018 | 38 | 0.040 |
Why?
|
| Interleukin-18 | 1 | 2018 | 74 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 964 | 0.040 |
Why?
|
| Standard of Care | 1 | 2017 | 27 | 0.040 |
Why?
|
| Abdomen | 1 | 2018 | 92 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2018 | 53 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 299 | 0.030 |
Why?
|
| Caregivers | 1 | 2020 | 268 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 137 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 201 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2018 | 307 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2018 | 277 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 475 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 317 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 890 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 262 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 3263 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 975 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1078 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 805 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 853 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1079 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1275 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1252 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 727 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2039 | 0.030 |
Why?
|
| Bacterial Secretion Systems | 1 | 2013 | 10 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1606 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1541 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2444 | 0.020 |
Why?
|
| Macrophages | 1 | 2018 | 1039 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2013 | 264 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2549 | 0.020 |
Why?
|
| Mice | 1 | 2025 | 10819 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2051 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 2013 | 271 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 875 | 0.020 |
Why?
|
| Animals | 1 | 2025 | 20620 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1142 | 0.020 |
Why?
|